Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Enzon Pharmaceuticals ( (ENZN) ) is now available.
Enzon Pharmaceuticals has expanded its Board of Directors to four members and appointed Stephen T. Wills as a new director. Wills brings extensive experience from his roles at various biopharmaceutical and technology companies, contributing his expertise in financial and operational management. Additionally, Enzon’s Board has formed a special committee to explore strategic alternatives concerning a proposal from Viskase Companies, Inc. The committee, including Wills, has full authority to negotiate and evaluate any potential transactions, though no decisions have been made yet.
More about Enzon Pharmaceuticals
YTD Price Performance: -11.67%
Average Trading Volume: 71,998
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $11.85M
See more data about ENZN stock on TipRanks’ Stock Analysis page.